170results about "Elcosanoid active ingredients" patented technology

The present disclosure describes a Pseudococcus preparation and a preparation method and application thereof, the Pseudococcus preparation comprises an active ingredient, the active ingredient comprises a specific pro-inflammatory regression mediator (SPMs) and a pro-inflammatory regression mediator (PRMs), the specific proinflammatory regression medium and the proinflammatory regression medium are generated by catalyzing unsaturated fatty acid synthesized by micrococcus by own enzyme. According to the invention, the invention can provide the micrococcus preparation containing the specific proinflammatory regression medium and the proinflammatory regression medium as well as the preparation method and the application of the micrococcus preparation.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and / or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and / or treating glaucoma etc.

The purpose of the present invention is to discover an eye drop capable of effectively lowering intraocular pressure even at night, especially during night sleep, in patients with glaucoma or ocular hypertension.　The present invention is an eye drop for lowering intraocular pressure during night sleep in patients suffering from glaucoma or ocular hypertension, the eye drop containing sepetaprost at a concentration of 0.002% (w / v) as an active ingredient.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of preservative effectiveness of this composition for ophthalmic use. The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w / v) and has a pH within a range from 5 to 8.

The present invention provides 5,6 dihydroxyeicosatetraenoic acid (5,6-diHETE) lactone or a pharmaceutical composition comprising 5,6-diHETE lactone and a pharmaceutically acceptable carrier, and uses thereof for inducing vasodilation, for treating a disease, disorder or condition associated with microvascular dysfunction, or for preventing, or reducing the risk of, developing a cardiac condition associated with microvascular dysfunction.

The present invention provides a method of treating constipation and compositions useful in said method. The method comprises administering to a subject in need thereof an effective amount of a crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid / water (1:8) and simulated intestinal fluids.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.

The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

The present disclosure concerns agents and therapeutic methods of mitigating at least one symptom of Fragile X syndrome (FXS) GRIN disorder, SynGAPI intellectual disability or Phelan-McDermid syndrome. The agents are inhibitors of one or more phosphodiesterase capable of hydrolyzing cGMP and optionally cAMP. In some embodiments, the agents can be inhibitors of a phosphodiesterase 1, 2, 5 or 10. The present disclosure also concerns a screening method for identifying test agents capable of mitigating at least one symptom of FXS. The screening methods determines that the test agent (or the combination of test agents) is useful when it is capable of increasing the activity of the neuronal nitric oxide synthase. Preferably, a mGluR5 blocking agent is combined with the phosphodiesterase inhibitors for the treatments described herein.

Disclosed is a method for treating ciliopathies-related diseases, comprising administering to a subject in need thereof an effective amount of a compound that targets at least one G protein-coupled receptor.Provided is a method for identifying therapeutic agents for treating diseases with ciliopathies, comprising providing an animal model system of ciliopathies to test putative therapeutic agents, administering a disrupting agent to the animal, treating the administered animal with the putative therapeutic agent, comparing the measurable phenotype of the treated animal with that of untreated animals, and identifying the therapeutic target as a treatment for ciliopathies if the measurable phenotype of the treated animal is reduced compared to that of the untreated animal. [Selection diagram] Figure 32

The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

Provided in the present invention is a compound which inhibits TDG activity. Specifically, provided in the present invention is a compound having a novel structure, as shown in formula I. A small molecule inhibitor of the present invention has an excellent inhibitory effect on TDG.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

To provide a method for treating a ciliopathy-associated disease.SOLUTION: The method for treating a ciliopathy-related disease comprises administering to a subject in need thereof an effective amount of a compound that targets at least one G protein-coupled receptor (GPCR). Provided is a method for identifying a therapeutic agent for the treatment of a disease having ciliopathy, the method comprising: providing an animal model system for a ciliopathy to investigate a putative therapeutic agent; administering a destructive agent to the animal; treating the administered animal with the putative therapeutic agent; comparing the measurable phenotype of the treated animal with that of an untreated animal; and identifying the therapeutic target as a therapeutic agent for ciliopathy when a measurable phenotype of the treated animal is reduced compared to that of the untreated animal.SELECTED DRAWING: None

The present invention provides compounds having EP3 agonist activity. A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent EP3 agonist activity, and thus is useful as an EP3 agonist.

Methods for treating and preventing pain are described. The methods include administering a therapeutically effective amount of a GPR37L1 ligand to a subject in need thereof. Also described herein are pharmaceutical compositions containing the GPR37L1 ligands.

The invention relates to the technical field of prevention and control of aquatic diseases, in particular to a preparation method of a pelteobagrus fulvidraco intestinal inflammation composite regulation preparation containing omega-3 fatty acid-lipoxin-phospholipid. The composite regulation and control preparation is prepared from the following functional components: 20 to 30 parts of eicosapentaenoic acid, 0.1 to 0.5 part of lipoxin B4, 8 to 12 parts of phosphatidylserine, 1 to 2 parts of dehydroabietic acid, 10 to 18 parts of sophorobiose and 0.01 to 0.03 part of ethoxyquin. The product integrates the functions of resisting bacteria, promoting inflammation regression and promoting tissue repair through a multi-target synergistic mechanism to construct a complete inflammation regulation and control pathway; meanwhile, by virtue of a nano-liposome dosage form technology, the active ingredients are effectively protected; the product is completely compounded from natural components to realize an antibacterial effect. According to the technical scheme, the technical problems of low antibacterial efficiency, single action mechanism, insufficient mucous membrane repair capability and the like of the existing prevention and control technology for the intestinal inflammation of the pelteobagrus fulvidraco can be solved, and the pelteobagrus fulvidraco has an ideal application prospect.

The present disclosure relates to a travoprost sustained release biodegradable intracameral Implant comprising a biodegradable hydrogel and travoprost particles. The present disclosure also relates to travoprost particles optionally obtained by or obtainable by a process comprising a membrane emulsification step. The present disclosure also relates to a method of manufacturing travoprost particles, optionally wherein the method comprises a membrane emulsification step. The present disclosure also relates to a method of manufacturing a travoprost sustained release biodegradable intracameral implant. The present disclosure also relates to a method of treating an ocular disease, such as glaucoma or ocular hypertension, comprising administering the travoprost particles or inserting the intracameral implant of the present disclosure into an eye of a subject in need of treatment.

To provide DKP microcrystals made by an improved method in which they do not irreversibly self-assemble into microparticles.SOLUTION: The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray-drying a solution containing components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and / or small organic small molecules.SELECTED DRAWING: None

The present invention relates to a dietary supplement indicated for the treatment of macular degeneration, more specifically a dietary supplement designed to assist in combating macular degeneration. The formulation is based on fish oil (a source of omega-3 TG) combined with cysteine, taurine, lutein, zeaxanthin, and vitamins, supporting visual health through a synergistic action of its components, enhanced by the benefits of omega-3. The present invention also relates to a capsule comprising said dietary supplement and the use of said supplement for combating macular degeneration.